David J. Mazzo, Ph.D., is a seasoned pharmaceutical executive with over 40 years of experience developing and launching new products in all therapeutical areas worldwide. Currently, Dr. Mazzo is the President and Chief Executive Officer of Lisata Therapeutics (NASDAQ: LSTA) and serves as a member of the board of directors. Dr. Mazzo has experience in all aspects of large and small, public and private company operations, both at the executive and board level. Prior to joining Lisata, he served as the Chief Executive Officer and a member of the board of directors at Regado Biosciences, Inc. (2008- 2024), Æterna Zentaris, Inc. (2007- 2008), and Chugai Pharma USA, LLC (2003-2007). He also held senior executive positions at Schering-Plough Research Institute, Hoechst Marion Roussel, and Rhone-Poulenc Rorer, Inc. Dr. Mazzo currently serves as Chairman of the board of Feldan Therapeutics, a private company developing technology for the intracellular delivery of therapeutic agents. He previously served on the board of directors for Visioneering Technologies, Inc. (2020-2024; chairman 2020-2024), EyePoint Pharmaceuticals, Inc. (2005-2020; chairman 2007-2018), Seneca Biopharmaceuticals, Inc. (2019-2021), and Avanir Pharmaceuticals, Inc. (2005-2015). Dr. Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition, Dr. Mazzo received his M.S. in chemistry and his Ph.D. degree in Analytical Chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.Dr. Mazzo is fluent in English and French.